Sex sells. And Sprout Pharmaceuticals just scored the diamond ring with the FDA approval of its previously rejected female Viagra drug Flibanserin. But is it just selling us the image of desire or can it authentically fix our female libido problems?
This libido issue has been recognized as a “medical” problem, initially termed hypoactive sexual desire (H.S.D.D. ) with its own diagnostic code until 2013 when it was renamed female sexual interest/arousal disorder (F.S.I.A.D.). The name change, as silly as it sounds, is important because it indicates a new and more accurate understanding of a more realistic sexual response cycle for women. The idea that this new pink Viagra treats a disorder that isn’t even still in the books only adds insult to injury when you consider both the significant side effects, including fainting and low blood pressure from Flibasnserin (a failed antidepressant), and the almost non-existent increase in sexual response.
Read More on Eco Salon…
